Logos Global Management LP Geron Corp Transaction History

Logos Global Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $15.8 Million - $31 Million	9,000,000 New	9,000,000 $29.7 Million
Q3 2023 Nov 14, 2023	BUY	$2.11 - $3.28 $1.16 Million - $1.8 Million	550,000 Added 25.0%	2,750,000 $5.83 Million
Q2 2023 Aug 14, 2023	SELL	$1.97 - $3.69 $2.66 Million - $4.98 Million	-1,350,000 Reduced 38.03%	2,200,000 $7.06 Million
Q1 2023 May 15, 2023	SELL	$2.14 - $3.4 $963,000 - $1.53 Million	-450,000 Reduced 11.25%	3,550,000 $7.7 Million
Q4 2022 Feb 14, 2023	BUY	$2.03 - $2.42 $4.06 Million - $4.84 Million	2,000,000 Added 100.0%	4,000,000 $9.68 Million
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $3.34 Million - $5.88 Million	2,000,000 New	2,000,000 $4.68 Million

274

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.32B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.